Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...